Cite
HARVARD Citation
Varghese, A. et al. (2017). Eradication of minimal residual disease improves overall and progression‐free survival in patients with chronic lymphocytic leukaemia, evidence from NCRN CLL207: a phase II trial assessing alemtuzumab consolidation. British journal of haematology. pp. 573-582. [Online].